Emile E Voest Selected Research

Paraffin

10/2019	The molecular genetic make-up of male breast cancer.
2/2012	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emile E Voest Research Topics

Disease

102	Neoplasms (Cancer) 03/2022 - 03/2002
15	Neoplasm Metastasis (Metastasis) 01/2019 - 06/2004
8	Breast Neoplasms (Breast Cancer) 03/2022 - 07/2003
8	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 04/2007
6	Renal Cell Carcinoma (Grawitz Tumor) 04/2017 - 12/2004
6	Melanoma (Melanoma, Malignant) 01/2016 - 11/2002
5	Alzheimer Disease (Alzheimer's Disease) 03/2005 - 10/2002
4	Carcinoma (Carcinomatosis) 01/2022 - 05/2008
4	Hypoxia (Hypoxemia) 05/2009 - 01/2004
3	Disease Progression 11/2021 - 04/2017
3	Necrosis 10/2009 - 12/2002
2	Colonic Neoplasms (Colon Cancer) 01/2020 - 01/2020
2	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2019
2	Prostatic Neoplasms (Prostate Cancer) 11/2019 - 01/2007
2	Body Weight (Weight, Body) 10/2017 - 12/2002
2	Esophageal Neoplasms (Esophageal Cancer) 11/2012 - 06/2009
2	Fatigue 09/2011 - 11/2005
2	Hypertension (High Blood Pressure) 12/2009 - 05/2008
2	Neuroblastoma 03/2005 - 03/2003
2	Amyloid Plaque 03/2005 - 03/2003
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Microsatellite Instability 01/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	COVID-19 01/2020
1	Respiratory Syncytial Virus Infections 01/2019
1	Pathologic Complete Response 01/2018
1	Cysts 01/2018

Drug/Important Bio-Agent (IBA)

14	Pharmaceutical PreparationsIBA 01/2022 - 04/2006
13	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2007
13	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2003
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2007
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2017 - 03/2004
7	Monoclonal AntibodiesIBA 10/2017 - 09/2004
6	Angiogenesis InhibitorsIBA 01/2018 - 09/2004
6	Bevacizumab (Avastin)FDA Link 05/2011 - 04/2007
5	Cisplatin (Platino)FDA LinkGeneric 06/2015 - 03/2002
4	Messenger RNA (mRNA)IBA 03/2022 - 08/2006
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2017 - 06/2009
4	Cetuximab (Erbitux)FDA Link 09/2017 - 02/2009
4	Amyloid (Amyloid Fibrils)IBA 10/2012 - 03/2003
4	Gemcitabine FDA Link 12/2011 - 08/2007
4	Paclitaxel (Taxol)FDA LinkGeneric 12/2011 - 09/2008
4	AngiostatinsIBA 07/2004 - 04/2002
3	Immune Checkpoint InhibitorsIBA 01/2021 - 11/2016
3	ErbB Receptors (EGF Receptor)IBA 01/2020 - 02/2009
3	Tyrosine Kinase InhibitorsIBA 12/2017 - 05/2008
3	Everolimus FDA Link 08/2017 - 06/2015
3	IntegrinsIBA 04/2016 - 04/2006
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2011 - 02/2009
3	EnzymesIBA 09/2011 - 12/2002
3	Capecitabine (Xeloda)FDA Link 10/2010 - 02/2009
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2010 - 08/2006
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2010 - 01/2005
3	vatalanib (PTK787)IBA 02/2010 - 04/2007
3	Amyloid beta-PeptidesIBA 03/2005 - 10/2002
3	Peptides (Polypeptides)IBA 03/2005 - 10/2002
3	EndostatinsIBA 09/2004 - 03/2003
2	AntigensIBA 01/2022 - 01/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 09/2004
2	Irinotecan (Camptosar)FDA LinkGeneric 10/2019 - 04/2010
2	ParaffinIBA 10/2019 - 02/2012
2	Formaldehyde (Formol)FDA Link 10/2019 - 02/2012
2	Hematoxylin (Haematoxylon)IBA 01/2018 - 12/2002
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2018 - 12/2002
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2017 - 08/2007
2	lumretuzumabIBA 09/2017 - 02/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2015 - 10/2009
2	VemurafenibIBA 09/2015 - 05/2015
2	ChemokinesIBA 02/2014 - 09/2006
2	ProdrugsIBA 09/2011 - 11/2008
2	PlatinumIBA 09/2011 - 11/2010
2	Immunoglobulin G (IgG)IBA 03/2010 - 09/2004
2	Oxi 4503IBA 10/2009 - 10/2009
2	Blood Proteins (Serum Proteins)IBA 08/2009 - 02/2007
2	Hemoglobins (Hemoglobin)IBA 01/2007 - 11/2005
2	AcidsIBA 08/2006 - 06/2004
2	Fibronectins (Fibronectin)IBA 06/2005 - 01/2004
2	PlasminogenIBA 03/2005 - 01/2003
2	VitronectinIBA 09/2004 - 08/2004
2	Collagen Type XVIII (Type XVIII Collagen)IBA 06/2003 - 03/2003
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2021
1	olaparibIBA 11/2021
1	ChromograninsIBA 01/2021
1	SynaptophysinIBA 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2020
1	NivolumabIBA 01/2020
1	IpilimumabIBA 01/2020
1	Celecoxib (Celebrex)FDA Link 01/2020
1	Estrogen ReceptorsIBA 10/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019

Therapy/Procedure

30	Therapeutics 03/2022 - 04/2002
21	Drug Therapy (Chemotherapy) 01/2021 - 07/2003
7	Immunotherapy 01/2022 - 01/2018
4	Precision Medicine 01/2021 - 02/2016
3	Radiofrequency Ablation 10/2010 - 05/2009
2	Hepatectomy 05/2010 - 12/2002
2	Adjuvant Chemotherapy 07/2004 - 07/2003
1	Castration 11/2019